I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
NeuroLogic - Clinical trials
NeuroLogic Spring 2011
Date: June 1, 2011
The following clinical trials are actively recruiting patients.
Primary Progressive Multiple Sclerosis (PPMS)
A double-blind, placebo-controlled trial of once-daily oral fingolimod in PPMS. Info: Jack Ratchford, MD, PI; Alpa Uchil, research nurse, firstname.lastname@example.org, 443-287-6079
Parkinson's Disease Psychosis
We are seeking patients over age 40 with a diagnosis of Parkinson's disease who have experienced psychosis (hallucinations/delusions) in the past month. This multicenter, double-blind, placebo-controlled trial will examine the safety and efficacy of the investigational drug pimavanserin in the treatment of Parkinson's disease psychosis. Info: Zoltan Mari, MD, PI; Arita McCoy, RN, coordinator, email@example.com 410-955-2954
Individuals with newly diagnosed Parkinson's disease are being recruited to participate in the Parkinson's Progression Markers study. Info: Melissa Gerstenhaber, RN, MSN, 410-614-1242 or firstname.lastname@example.org. Joseph Savitt, MD, PhD, PI
Normal Learning and Memory
We are recruiting healthy adult subjects to examine the effects of noninvasive brain stimulation in modifying the rate of learning and memory of very simple stimuli and events. Info: John Desmond, PhD, PI; Monica Faulkner, research coordinator, email@example.com, 410-502-2184
Ongoing studies aimed at improving aspects of memory and exploring the role of music in learning and recalling semantic information in patients with pure or relatively pure anterograde amnesia due to any organic cause, such as encephalitis, hypoxemia or hypotension. Info: Barry Gordon, MD, PhD, PI, firstname.lastname@example.org; or Jacqueline Weaver, coordinator, email@example.com
Inflammatory Markers in Migraine: We are conducting a double-blind, placebo-controlled, pre- and post-treatment (sumatriptan/naproxen sodium) evaluation of inflammatory marker levels in episodic migraineurs. Age greater than or
equal to 18 years, with a diagnosis of episodic migraine. Info: B. Lee Peterlin, DO, PI; Linda White, CRNP, research coordinator, firstname.lastname@example.org or pager 410-283-4064
The Peripheral Neuropathy Research Registry is recruiting patients with painful or nonpainful peripheral neuropathy for a natural history study. Info: Ahmet Höke, MD, PhD, PI; Andrea Kelley, coordinator, email@example.com, 443-287-0627
IRIS-Insulin Resistance Intervention after Stroke Trial: A phase III, randomized, double-blind, placebo-controlled trial that will test the hypotheses of reducing insulin resistance and its sequelae by using pioglitizone versus placebo to prevent stroke and myocardial infarction among patients with a recent ischemic stroke or transient ischemic attack within six months of event. Info: Robert Wityk, MD, PI, firstname.lastname@example.org; Susan Rice, RN, MPH, coordinator, email@example.com